Home
Posts
CMS Targets Prior Auth Timelines for Medicines, Though High Denial Rates May Be the Bigger Issue

CMS Targets Prior Auth Timelines for Medicines, Though High Denial Rates May Be the Bigger Issue

And BIO’s leader expresses concern about the MFN choices smaller biotechs must make

Apr 13, 2026

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.